4-methyl-3-[4-[(3-oxo-2-propylcyclohexen-1-yl)amino]phenyl]-4,5-dihydro-1H-pyridazin-6-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-3-[4-[(3-oxo-2-propylcyclohexen-1-yl)amino]phenyl]-4,5-dihydro-1H-pyridazin-6-one
• 化学式: C₂₀H₂₅N₃O₂
• 分子量: 339.4
• InChiKey: GWHBUAUGUIYQBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  70.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• PLATELET AGGREGATION INHIBITOR
  申请人：NIPPON SODA CO., LTD.

  公开号：EP0667158A1

  公开（公告）日：1995-08-16

  A platelet aggregation inhibitor containing a compound represented by general formula (I) or a pharmaceutically acceptable complex thereof as the active ingredient, wherein Y represents -CH2-CH2- or -CH2-CH2-CH2-; R represents hydrogen or methyl; and symbol (a) represents either a single or a double bond.

  一种含有通式（I）代表的化合物或其药学上可接受的复合物作为活性成分的血小板聚集抑制剂，其中 Y 代表-CH2- -或- - - -；R 代表氢或甲基；符号（a）代表单键或双键。
• OPTICALLY ACTIVE COMPOUND
  申请人：NIPPON SODA CO., LTD.

  公开号：EP0791584A1

  公开（公告）日：1997-08-27

  The present invention is directed to (R)-(-)-4,5-dihydro-5-methyl-6-[4-[(2-propyl-3-oxo-1-cyclohexenyl)amino]phenyl]-3(2H)-pyridazinone, the crystalline form thereof and a method for manufacturing the said compound and the said crystalline form. The compound of the present invention has excellent inhibitory effect on platelet aggregation while giving less side effect, and therefore, it is useful to utilize the compound as an antithrombotic drug. In addition, the compound of the present invention has bronchodialatic effect as well, and it is therefore useful to utilize the compound for chemotherapy of chronic obstructive lung disease, such as asthma and bronchitis. Moreover, the compound of the present invention is useful for chemotherapy of the diseases relating to the concentration of cAMP in cells, such as hypertension, ulcer, diabetes mellitus and cancer. Again, crystalline form of the said compound is the most suitable form in order to supply stable and homogeneous bulk thereof.

  本发明涉及(R)-(-)-4,5-二氢-5-甲基-6-[4-[(2-丙基-3-氧代-1-环己烯基)氨基]苯基]-3(2H)-哒嗪酮、其结晶形式以及制造上述化合物和上述结晶形式的方法。 本发明的化合物对血小板聚集有很好的抑制作用，同时副作用较小，因此可以用作抗血栓药物。此外，本发明化合物还具有支气管扩张作用，因此可用于慢性阻塞性肺病（如哮喘和支气管炎）的化疗。 此外，本发明化合物还可用于高血压、溃疡、糖尿病和癌症等与细胞中 cAMP 浓度有关的疾病的化疗。 同样，上述化合物的结晶体是最合适的形式，以便提供稳定和均匀的块状物。
• SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR
  申请人：ALTANA Pharma AG

  公开号：EP1176960B1

  公开（公告）日：2004-09-29
• US5663172A
  申请人：——

  公开号：US5663172A

  公开（公告）日：1997-09-02
• US5856480A
  申请人：——

  公开号：US5856480A

  公开（公告）日：1999-01-05